At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 7 enrolled
Drug / intervention
Tildrakizumabbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
In Brief
A Phase 4 clinical trial evaluating Tildrakizumab for Psoriasis Vulgaris. Completed, enrolled 7 participants across 1 site.
Detailed Summary
This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesUnited States
CollaboratorsSun Pharmaceutical Industries Limited
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartSep 2020
Primary CompletionJan 2023
TodayJul 2026
First PostedSep 9, 2020
Enrollment StartSep 16, 2020
Primary CompletionJan 15, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.8 years ago
Interventions
Tildrakizumabbiological
IL-23 inhibitor